Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Italian Stock Exchange  >  DiaSorin SpA    DIA   IT0003492391

DIASORIN SPA (DIA)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Italian Stock Exchange
12/11/2017 12/12/2017 12/13/2017 12/14/2017 12/15/2017 Date
80.35(c) 78.55(c) 77.35(c) 76.4(c) 75.8 Last
61 927 77 315 77 972 85 673 98 841 Volume
-0.25% -2.24% -1.53% -1.23% -0.79% Change
More quotes
Financials (€)
Sales 2017 638 M
EBIT 2017 196 M
Net income 2017 132 M
Finance 2017 117 M
Yield 2017 1,20%
Sales 2018 710 M
EBIT 2018 222 M
Net income 2018 152 M
Finance 2018 217 M
Yield 2018 1,33%
P/E ratio 2017 31,69
P/E ratio 2018 27,55
EV / Sales2017 6,46x
EV / Sales2018 5,67x
Capitalization 4 241 M
More Financials
Company
DiaSorin SpA engages in the development, production, and marketing of reagent kits for in vitro diagnostics.It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone... 
More about the company
Surperformance© ratings of DiaSorin SpA
Trading Rating : Investor Rating :
More Ratings
Latest news on DIASORIN SPA
12/12 DIASORIN : Launches a new simplexa bordetella direct molecular test
11/29 DIASORIN : Resignation of a Strategic Executive of the Company
11/20 DIASORIN : Reagent Kits
11/13 DIASORIN : Molecular Receives FDA Clearance for C. difficile Assay
11/09 DIASORIN : Growth in revenues and net profit in q3 2017. strong free cash flow g..
11/08 DIASORIN : Molecular Introduces Analyte-Specific Reagents for Streptococcus
11/01DIASORIN SPA : quaterly earnings release
09/29 DIASORIN : Revises its guidance upwards for 2019 as a consequence of the complet..
09/29 DIASORIN : Completes the acquisition of the elisa immunodiagnostic business port..
09/21 DIASORIN : earned CE-mark extending sample claims for DiaSorin Molecular's Simpl..
More news
Sector news : Diagnostic & Testing Substances
12/15 ESSILOR INTERNATIONAL : Luxottica CEO leaves group ahead of merger with Essilor
12/14 EXCLUSIVE : Luxottica, Essilor tie-up on track for unconditional EU okay - sourc..
12/11DJESSILOR INTERNATIONAL : Luxottica Group Will Have New CEO, Says Chief -FT
12/08 Toshiba, Western Digital aiming to settle chip dispute next week - sources
12/08 TOSHIBA, WESTERN DIGITAL AIMING TO S : sources
More sector news : Diagnostic & Testing Substances
News from SeekingAlpha
11/13 Diasorin SPA ADR 2017 Q3 - Results - Earnings Call Slides
06/27 DiaSorin (DSRLF) Investor Presentation - Slideshow
2016 Winner And Losers Among Italian Companies
2016 Diasorin SPA ADR 2016 Q3 - Results - Earnings Call Slides
2016 DiaSorin buys Quest's diagnostic products business for $300M
Chart DIASORIN SPA
Duration : Period :
DiaSorin SpA Technical Analysis Chart | DIA | IT0003492391 | 4-Traders
Technical analysis trends DIASORIN SPA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 75,4 €
Spread / Average Target -0,50%
EPS Revisions
Managers
NameTitle
Carlo Rosa Chief Executive Officer, Executive Director & GM
Gustavo Denegri Chairman
Piergiorgio Pedron Chief Financial Officer & Senior Corporate VP
Francesco Colotta Chief Medical Officer & Senior Corporate VP
Chen Menachem Even Executive Director & SVP-Commercial Operations
Sector and Competitors
1st jan.Capitalization (M$)
DIASORIN SPA35.82%4 983
BIOMERIEUX58.14%10 433
AUTOBIO DIAGNOSTICS CO LTD-1.15%3 493
MACCURA BIOTECHNOLOGY CO LTD--.--%1 991
SIEGFRIED HOLDING AG43.31%1 300
SHANGHAI KEHUA BIO-ENGINEERING CO LTD--.--%1 145